English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The clinical utility of 18F–choline positron emission tomography fused with computed tomography (PET/CT) in all men with high-risk prostate cancer is still uncertain, because of selection of patients in previous studies. Prohibitive costs are one reason for PET/CT not being recommended for primary metastasis staging in European or American guidelines. The purpose of this retrospective study was to assess the clinical utility of in for primary metastasis staging in as complete a population as possible of men with high-risk prostate cancer. A secondary purpose was to evaluate whether a subgroup of these men could omit metastasis staging.

A population-based study of the clinical utility of 18F–choline PET/CT for primary metastasis staging of high-risk prostate cancer